

Special Issue

Progress in Nanotechnology-Based Therapeutic Strategies

Message from the Guest Editors

Key topics in this Special Issue include the use of nanoparticles for targeted drug delivery, enabling drugs to reach specific tissues or cells with minimal off-target effects, thus reducing toxicity and improving therapeutic outcomes. In addition, we will explore nanomaterial-based therapies, such as nanostructures functioning as therapeutic agents or facilitating regenerative medicine, tissue engineering, and gene therapy. Other relevant areas include the integration of nanotechnology with biochemical analyses for monitoring treatment efficacy and omics approaches (e.g., genomics, proteomics, and metabolomics) to understand disease mechanisms and therapeutic responses at the molecular level. This Special Issue will cover both preclinical and clinical advances, highlighting novel nanotechnology-based platforms, innovative biomaterials, and strategies to overcome biological barriers. We invite submissions on topics ranging from the design and synthesis of novel nanomaterials to their applications in personalized medicine, biochemical diagnostics, and real-time therapeutic monitoring.

Guest Editors

Dr. Ambra Del Grosso

NEST (National Enterprise for nanoScience and nanoTechnology),
Istituto Nanoscienze-CNR and Scuola Normale Superiore, Piazza San
Silvestro 12, 56127 Pisa, Italy

Dr. Mariacristina Gagliardi

NEST, Istituto Nanoscienze-CNR and Scuola Normale Superiore, Piazza
San Silvestro, 56127 Pisa, Italy

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/218884

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).